Enzymatic activation of prodrugs by prostate-specific antigen: Targeted therapy for metastatic prostate cancer

Cancer Journal from Scientific American

Volumn 4, Issue SUPPL. 1, 1998, Pages

  Denmeade, Samuel R ^a   Isaacs, John T ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIUM ION; PRODRUG; PROSTATE SPECIFIC ANTIGEN; THAPSIGARGIN;

APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOTRANSFORMATION; HUMANS; MALE; NEOPLASM METASTASIS; PRODRUGS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031813782     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Landis SH, Murray T, Bolden S et al. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
2. Carter HB, Isaacs JT. Experimental and theoretical basis for hormonal treatment of prostatic cancer. Semin Urol 1988;4:262-268.
3. Horm J, Sondik E. Person-years of life lost due to cancer in the United States in 1970 and 1984. Am J Public Health 1989;79: 1490-1493.
4. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71:1098-1109.
5. Isaacs JT, Lundmo PI, Berges R et al. Androgen regulation of programmed death of normal and malignant prostatic cells. J Andrology 1992;13:457-464.
6. Isaacs JT, Coffey DS. Adaptation vs selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studied in the Dunning R-3327 H adenocarcinoma. Cancer Res 1981;41:5070-5075.
7. Crawford ED, Eisenberger MA, McLeod DC et al. A control randomized trial of leuprolide with and without flutamide in prostatic cancer. N Engl J Med 1989;321:419-424.
8. Isaacs JT. Hormonally responsive vs unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and G rat prostatic adenocarcinoma. Cancer Res 1982;42:5010-5014.
9. Raghavan D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol 1988;15:371-389.
10. Shackney SE, McCormack GW, Cuchural GJ. Growth rate patterns of solid tumors and their relationship to responsiveness to therapy. Ann Intern Med 1978;89:107-115.
11. Isaacs JT, Lundmo PI. Chemotherapeutic induction of programmed cell death in non proliferating prostate cancer cells. Proc Am Assoc Cancer Res 1992;33:588-589.
12. Tubina M, Malaise EP. Growth rate and cell kinetics in human tumors: some prognostic and therapeutic implications. In Symington et al, eds. Scientific Foundations of Oncology. Chicago: Year Book Medical Publishers, 1976;126-138.
13. Berges RS, Vukanovic J, Epstein, JI et al. Implication of the cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995;1:473-480.
14. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990;50:3748-3753.
15. Kyprianou N, Isaacs JT. Thymine-less death in androgen independent prostatic cancer cells. Biochem Biophys Res Commun 1989;165:73-81.
16. Martikainen P, Isaacs JT. Role of calcium in the programmed death of rat prostatic glandular cells. Prostate 1990;17:175-187.
17. Connor J, Sawczuk IS, Benson MC et al. Calcium channel antagonists delay regression of androgen-independent tissues and suppress gene activity associated with cell death. Prostate 1988;13: 119-130.
18. Sells SF, Wood DP, Joshi-Barve SS et al. Commonality of the gene programs induced by effectors of apoprosis in androgen-dependent and -independent prostate cells. Cell Growth Diff 1994;5:457-466.
19. Greenberg DA. Calcium channels and calcium channel antagonists. Ann Neurol 1987;21:317-330.
20. Martikainen P, Kyprianou N, Tucker RW et al. Programmed death of non-proliferating androgen independent prostatic cancer cells. Cancer Res 1991;51:4693-4700.
21. Furuya Y, Isaacs JT. Proliferation-dependent vs independent programmed cell death of prostatic cancer cells involves distinct gene regulation. Prostate 1994;25:301-309.
22. Furuya Y, Lundmo P, Short AD et al. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res 1994;54:6167-6175.
23. Christensen SB, Norup E, Rasmussen U. Chemistry and structure-activity relationship of the histamine secretagogue Thapsigargin and related compounds. In: Krogsgaard-Larsen et al, eds. Natural Product Drug Development. Copenhagen: Munksgaard, 1993; 405-418.
24. Rasmussen U, Christensen SB, Sandberg F. Thapsigargin and thapsigargicin, two new histamine liberators from Thapsia garganica. L Acta Pharm Suec 1978;15:133.
25. Thastrup O, Cullen PJ, Drbak B et al. Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2+-ATPase. Proc Natl Acad Sci USA 1990;87:2466-2470.
26. Davidson GA, Varhol RJ. Kinetics of thapsigargin-Ca2+-ATPase (sarcoplasmic reticulum) interaction reveals a two-step binding mechanism and picomolar inhibition. J Biol Chem 1995;270: 11731-11734.
27. Lytton J, Westlin M, Haley MR. Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J Biol Chem 1991;266:17067-17071.
28. Lin XS, Denmeade SR, Cisek L et al. The mechanism and role of growth arrest in programmed (apoptotic) death of prostate cancer cells induced by thapsigargin. Prostate 1997;33:201-207.
29. Denmeade SR, Isaacs, JT. Activation of programmed (apoptotic) cell death for the treatment of prostate cancer. Adv Pharmacol 1996;35:281-306.
30. Wang MC, Valenzuela LA, Murphy GP et al. Purification of a human prostate specific antigen. Invest Urol 1979;17:159-163.
31. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76: 1899-1903.
32. Watt KWK, Lee P-J, Timkulu TM et al. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986;83:3166-3170.
33. Yu H, Diamandis EP, Levesque M et al. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 1996;40:171-178.
34. Giai M, Yu H, Roagna R et al. Prostate-specific antigen in serum of women with breast cancer. Br J Cancer 1995;72:728-731.
35. Christensson A, Laurell CB, Lilja H. Enzymatic activity of the prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755-765.
36. Akiyama K, Nakamura T, Iwanaga S et al. The chymotrypsin-like activity of human prostate-specific antigen gamma-seminoprotein. FEBS Lett 1987;225:168-172.
37. Lilja H, Abrahamsson P-A, Lundwall A. Semenogelin, the predominant protein in human semen. J Biol Chem 1989;264: 1894-1900.
38. Lundwall A, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 1987;214:317-322.
39. Lilja H, Oldbring J, Rannevik G et al. Seminal vesicle-secreted proteins and their reactions during gelation and liquefication of human semen. J Clin Invest 1987;80:281-285.
40. Malm J, Hellman J, Lilja H. Mapping of the unique enzyme characteristics of PSA. J Urol 1997;157(suppl):345.
41. Kurkek R, Herrala A, Henttu P et al. Expression of active, secreted human prostate-specific antigen by recombinant baculovirus-infected insect cells on a pilot scale. Biotechnology 1995;13:1230-1234.
42. Denmeade SR, Lou W, Lovgren J, et al. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 1997;57:4924-4930.
43. Lilja H, Christensson A, Dahlén U et al. Prostate specific antigen in human serum occurs predominantly in complex with al-antichymotrypsin. Clin Chem 1991;37:1618-1625.
44. 1-anti-chymotrypsin complex. Clin Chem 1995;41:1480-1488.
45. Leinonen J, Wan-Ming Z, Stenman U-H. Complex formation between PSA isoenzymes and protease inhibitors. J Urol 1996; 155:1099-1103.
46. Sottrup-Jensen L. α-Macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem 1989;264: 11539-11542.
47. Hoehn W, Schroeder FH, Riemann JF et al. Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC-82). Prostate 1980;1:94-104.
48. Csapo Z, Brand K, Wlather R et al. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice. J Urol 1988;140:1032-1038.